Novo Nordisk A/s

This study tests whether a monthly injection of ziltivekimab can reduce the risk of heart attacks, strokes, and heart-related death in 6,200 people with heart disease, chronic kidney disease, and signs of inflammation. Participants are randomly assigned to receive either the acti…

This study tests an investigational medicine called cagrilintide to see how much it helps people with overweight or obesity and type 2 diabetes lose weight. About 330 adults will receive either cagrilintide or a placebo for around 18 months. The main goals are to measure the perc…

This study tests whether a weekly injection of semaglutide helps children aged 6 to 17 with obesity or overweight lose weight. About 210 kids will receive either the drug or a placebo, plus lifestyle advice. The study lasts about 2.5 years and focuses on safety and long-term weig…

This study tests whether a new once-weekly growth hormone medicine (somapacitan) works as well as the standard daily shot (Norditropin) for children born small who remain short. About 62 children aged 2.5 to 11 years will receive either weekly or daily injections for up to 5 year…

This study tests a new investigational medicine called CagriSema (a combination of two drugs) against an approved drug, tirzepatide, in people with type 2 diabetes. The goal is to see which works better at lowering blood sugar and body weight. About 1,023 adults whose diabetes is…

This early-stage study tests a new drug, NNC0194-0499, in 96 adults with type 1 diabetes. The goal is to see if adding this drug, alone or with semaglutide, helps keep blood sugar in a healthy range better than placebo. All participants continue their usual insulin. The study las…

This study tests a once-weekly injection called CagriSema (a combination of two medicines) for weight loss and long-term weight maintenance in adults with obesity. About 609 participants will receive either CagriSema or a placebo for up to 3 years. The goal is to see how much wei…

This study tests a new medicine, cagrilintide, to help people with obesity or overweight lose weight. About 300 adults will receive either the drug or a placebo for around 18 months. The main goals are to see how much weight they lose and how many achieve at least a 5% weight red…

This study follows 1071 people with obesity in Japan who are taking Wegovy as part of their regular care. Researchers will track side effects and weight changes over 2 years to see how the drug works in everyday life. The goal is to understand real-world safety and effectiveness,…

This study follows 1250 adults with obesity who are starting Wegovy as part of their regular medical care. Researchers will track changes in weight, waist size, and quality of life over two years. The goal is to see how well the medication works in real-world settings, not just i…

This study tests whether community-based programs that promote healthy eating and physical activity can prevent obesity in children aged 6-13 from disadvantaged urban areas. About 36,000 children in six countries (Australia, Brazil, Canada, Japan, South Africa, and Spain) will ta…

This study observes pregnant women who took Wegovy for weight management and compares their health and their babies' health to pregnant women with similar conditions who did not take Wegovy. Researchers will follow infants for one year after birth to check for birth defects or ot…